Articles | Volume 6, issue 9
J. Bone Joint Infect., 6, 413–421, 2021
https://doi.org/10.5194/jbji-6-413-2021
J. Bone Joint Infect., 6, 413–421, 2021
https://doi.org/10.5194/jbji-6-413-2021
Original full-length article
12 Nov 2021
Original full-length article | 12 Nov 2021

Mid-term clinical results of chronic cavitary long bone osteomyelitis treatment using S53P4 bioactive glass: a multi-center study

Tom A. G. Van Vugt et al.

Viewed

Total article views: 408 (including HTML, PDF, and XML)
HTML PDF XML Total BibTeX EndNote
306 86 16 408 5 4
  • HTML: 306
  • PDF: 86
  • XML: 16
  • Total: 408
  • BibTeX: 5
  • EndNote: 4
Views and downloads (calculated since 12 Nov 2021)
Cumulative views and downloads (calculated since 12 Nov 2021)

Viewed (geographical distribution)

Total article views: 370 (including HTML, PDF, and XML) Thereof 370 with geography defined and 0 with unknown origin.
Country # Views %
  • 1
1
 
 
 
 

Cited

Latest update: 08 Aug 2022
Download
Short summary
Chronic osteomyelitis is a bone infection and was treated with a combination of antibiotics and two surgeries. With the introduction of the biomaterial S53P4 bioactive glass, these infections can be treated with antibiotics and one surgery. This study shows 85 % success in the treatment of these bone infections. Together with the fundamentally different antibacterial mechanisms without antibiotic resistance, S53P4 bioactive glass is recommendable for the treatment of these infections.